U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option For Virologically Suppressed Adults With HIV, Including Those On Complex Regimens
GILD•FDA approves Gilead’s Bixlenvo for virologically suppressed adults with HIV
Aug. 27 (Reuters) - Gilead Sciences, Inc. GILD.O:
- U.S. FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens.
